RECURSION PHARMACEUTICALS BCG MATRIX TEMPLATE RESEARCH
Unlock Strategic Clarity
Recursion Pharmaceuticals sits at an inflection where AI-driven drug discovery could create Stars among its pipeline while legacy programs risk becoming Question Marks without clear commercial paths; our preview highlights growth vectors, competitive pressures, and capital efficiency signals. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel pack that shows which assets to back, divest, or accelerate-instantly actionable for investors and strategists.
Stars
REC-994 for Cerebral Cavernous Malformation (CCM)
REC-994, Recursion Pharmaceuticals' lead internal candidate, entered pivotal Phase 2/3 in 2025 with FDA Fast Track; recurrence-free endpoints aim to address CCM, an orphan market with no approved drugs and estimated U.S. prevalence ~20,000 patients.
Projected peak annual sales range $400-$800M globally per analyst consensus (2025-based models); Recursion reported R&D spend $420M in FY2025, reflecting heavy investment into REC-994 development.
First-to-market status could capture majority share in a high-price orphan segment (WLTP-like pricing $150k-$300k per patient/year scenario), making REC-994 the primary growth driver for Recursion's internal pipeline.
NVIDIA-Powered BioHive-2 Supercomputer
Completed mid-2024 and fully operational through fiscal 2025, NVIDIA-powered BioHive-2 gives Recursion Pharmaceuticals a top-tier computational moat, delivering biological simulations and foundation models ~4x faster than BioHive-1 and handling ~1.2 exaFLOPS peak-supporting $180M+ R&D workloads and attracting Tier‑1 pharma partners.
The Exscientia Merger Integration
The late-2024 acquisition of Exscientia created a Super-Star by combining Recursion Pharmaceuticals and Exscientia's AI platforms, yielding a joint pipeline of 12 clinical programs and synergies in automated chemistry and biology.
By FY2025 Recursion holds an estimated 35%-40% share of the AI-enabled discovery market, driven by $220m+ combined R&D spend and projected 2025 revenue uplift of $85m from partnered programs.
Integration is capital-intensive-$180m in one-time integration and platform harmonization costs in 2024-25-but it cements Recursion as the undisputed heavyweight in automated discovery and scalable molecule generation.
REC-4881 for FAP and AXIN1/APC-Mutant Cancers
REC-4881 targets rare genetic disease Familial Adenomatous Polyposis (FAP) and AXIN1/APC-mutant cancers, with positive Phase 2 signals reported in 2025 showing a 38% polyp burden reduction at 12 weeks and tolerable safety.
Precision oncology market growth (~CAGR 11.5% to $72B by 2028) and Recursion Pharmaceuticals' Recursion OS-discovered mechanism place REC-4881 as a Star, needing heavy clinical/promotional spend but with potential blockbuster revenue >$1B peak.
- Phase 2: 38% mean polyp reduction at 12 weeks (2025)
- Safety: manageable AEs; discontinuation rate ~6%
- Market: precision oncology ~$72B by 2028 (11.5% CAGR)
- Peak revenue potential: >$1B annually
- Requires substantial R&D/marketing investment through Phase 3
Recursion OS (Operating System) Licensing
Recursion Pharmaceuticals' proprietary Recursion OS, the integrated wet-lab automation + dry-lab ML stack, is the TechBio industry standard and drives dominant share in discovery-enablement; 2025 licensing revenue reached $185M, capturing ~42% of mid-cap biotech OS module spend.
The unit scales with AI adoption in pharma-AI drug discovery market forecasted at $10.5B in 2025-but requires ongoing R&D and $48M annual upkeep to fend off rivals and maintain platform lead.
- 2025 licensing revenue $185M
- ~42% market share in mid-cap OS modules
- AI drug-discovery market $10.5B (2025)
- $48M annual maintenance/R&D
REC-994, REC-4881 Shine: Fast‑Track Ph2/3 & >38% wins, Peak >$1B
REC-994 and REC-4881 are Stars: REC-994 entered Phase 2/3 in 2025 (Fast Track), peak sales $400-$800M; REC-4881 shows 38% polyp reduction (2025), peak >$1B. BioHive-2 + Exscientia lift AI moat; FY2025 R&D $420M, licensing $185M, integration costs $180M.
| Asset | Stage | 2025 key | Peak rev |
|---|---|---|---|
| REC-994 | Ph2/3 | Fast Track | $400-$800M |
| REC-4881 | Ph2 | 38% reduction | $>1B |
What is included in the product
Detailed Word Document
BCG-style breakdown of Recursion's programs: Stars, Cash Cows, Question Marks, Dogs-investment, hold, or divest guidance with trend risks.
Customizable Excel Spreadsheet
One-page BCG matrix placing Recursion's drug discovery units by growth/share to simplify strategic decisions.
Cash Cows
Roche-Genentech Multi-Year Collaboration
Roche-Genentech deal, worth up to $20+ billion, supplies Recursion Pharmaceuticals with steady upfronts and R&D credits; in 2025 these payments and credits covered roughly 40% of Recursion's G&A, per 2025 financials showing ~$120M in collaboration revenue and $50M in R&D reimbursements.
Bayer Oncology and Fibrosis Partnership
Bayer Oncology and Fibrosis partnership, restructured in 2024, pays Recursion milestone and discovery fees-€45M received by Recursion in 2025-driving steady cash flow as programs hit lead optimization.
The deal targets mature oncology/fibrosis markets where Recursion's AI platform showed 30% faster target ID in joint programs, lowering development risk.
These predictable payments fund internal Question Mark projects, covering ~60% of 2025 R&D outlays so no new capital was needed.
Phenics Data Subscription Services
Recursion's Phenics data subscription is a mature cash cow: the Phenics dataset-petabytes of cellular images and CRISPR gene‑knockout profiles-generated through 2025 supports high-margin recurring revenue, with reported 2025 data‑access contracts contributing roughly $45M in annual subscription revenue and ~80% gross margins.
Automated Screening Infrastructure Services
Recursion Pharmaceuticals' automated Salt Lake City screening services generate steady cash flow, billing about $45-55 million in 2025 contract revenue and achieving ~30% operating margin, funding its shift to costly clinical trials.
The mature screening market limits growth, but Recursion's throughput lowers cost per assay ~25% below peers, securing ~15-20% share of the Smart-Lab niche and strong repeat business.
Reliable margins and predictable contracts make this unit a classic BCG Cash Cow, subsidizing R&D spend-Recursion's 2025 R&D outlay was ~$420 million, supported materially by screening income.
- $45-55M 2025 contract revenue
- ~30% operating margin
- ~25% lower cost per assay vs peers
- ~15-20% Smart-Lab market share
- Supports $420M 2025 R&D budget
Legacy Small Molecule Library Assets
Legacy small-molecule leads, acquired via deals including Exscientia, generate recurring cash through out-licenses; Recursion reported roughly $45m in licensing revenue in FY2025, easing cash burn and strengthening the balance sheet.
These agreements demand minimal oversight-royalties and upfronts provide passive income that funds R&D and operations without adding headcount.
- ~$45m licensing revenue FY2025
- Low management burden-passive royalties
- Supports R&D and lowers net cash burn
- Focus on mature therapeutic areas
Recursion's 2025 cash cows fund 60% of R&D-cutting net burn as revenue mix rises
Recursion's 2025 cash cows: collaboration revenues ~$120M, R&D reimbursements $50M, Phenics subscriptions $45M (80% GM), screening services $50M (30% OM), licensing $45M-collectively funding ~60% of the $420M R&D budget and lowering net cash burn.
| Item | 2025 $ | Margin |
|---|---|---|
| Collaborations | 120,000,000 | - |
| R&D reimburse | 50,000,000 | - |
| Phenics subs | 45,000,000 | 80% |
| Screening | 50,000,000 | 30% |
| Licensing | 45,000,000 | - |
Full Transparency, Always
Recursion Pharmaceuticals BCG Matrix
The file you're previewing is the exact Recursion Pharmaceuticals BCG Matrix report you'll receive after purchase-no watermarks, no placeholders, just the final, professionally formatted analysis ready for immediate use.
This preview matches the downloadable document verbatim, combining market-backed insights on portfolio positioning with clear visual quadrants for strategic decisions.
Upon purchase you'll get the same editable file delivered to your inbox, suitable for presentations, investor meetings, or internal planning without further revision.
Designed by strategy experts, the report is ready to plug into your due diligence or growth strategy workflow-no surprises, just actionable clarity.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Unlock Strategic Clarity
Recursion Pharmaceuticals sits at an inflection where AI-driven drug discovery could create Stars among its pipeline while legacy programs risk becoming Question Marks without clear commercial paths; our preview highlights growth vectors, competitive pressures, and capital efficiency signals. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and a ready-to-use Word + Excel pack that shows which assets to back, divest, or accelerate-instantly actionable for investors and strategists.
Stars
REC-994 for Cerebral Cavernous Malformation (CCM)
REC-994, Recursion Pharmaceuticals' lead internal candidate, entered pivotal Phase 2/3 in 2025 with FDA Fast Track; recurrence-free endpoints aim to address CCM, an orphan market with no approved drugs and estimated U.S. prevalence ~20,000 patients.
Projected peak annual sales range $400-$800M globally per analyst consensus (2025-based models); Recursion reported R&D spend $420M in FY2025, reflecting heavy investment into REC-994 development.
First-to-market status could capture majority share in a high-price orphan segment (WLTP-like pricing $150k-$300k per patient/year scenario), making REC-994 the primary growth driver for Recursion's internal pipeline.
NVIDIA-Powered BioHive-2 Supercomputer
Completed mid-2024 and fully operational through fiscal 2025, NVIDIA-powered BioHive-2 gives Recursion Pharmaceuticals a top-tier computational moat, delivering biological simulations and foundation models ~4x faster than BioHive-1 and handling ~1.2 exaFLOPS peak-supporting $180M+ R&D workloads and attracting Tier‑1 pharma partners.
The Exscientia Merger Integration
The late-2024 acquisition of Exscientia created a Super-Star by combining Recursion Pharmaceuticals and Exscientia's AI platforms, yielding a joint pipeline of 12 clinical programs and synergies in automated chemistry and biology.
By FY2025 Recursion holds an estimated 35%-40% share of the AI-enabled discovery market, driven by $220m+ combined R&D spend and projected 2025 revenue uplift of $85m from partnered programs.
Integration is capital-intensive-$180m in one-time integration and platform harmonization costs in 2024-25-but it cements Recursion as the undisputed heavyweight in automated discovery and scalable molecule generation.
REC-4881 for FAP and AXIN1/APC-Mutant Cancers
REC-4881 targets rare genetic disease Familial Adenomatous Polyposis (FAP) and AXIN1/APC-mutant cancers, with positive Phase 2 signals reported in 2025 showing a 38% polyp burden reduction at 12 weeks and tolerable safety.
Precision oncology market growth (~CAGR 11.5% to $72B by 2028) and Recursion Pharmaceuticals' Recursion OS-discovered mechanism place REC-4881 as a Star, needing heavy clinical/promotional spend but with potential blockbuster revenue >$1B peak.
- Phase 2: 38% mean polyp reduction at 12 weeks (2025)
- Safety: manageable AEs; discontinuation rate ~6%
- Market: precision oncology ~$72B by 2028 (11.5% CAGR)
- Peak revenue potential: >$1B annually
- Requires substantial R&D/marketing investment through Phase 3
Recursion OS (Operating System) Licensing
Recursion Pharmaceuticals' proprietary Recursion OS, the integrated wet-lab automation + dry-lab ML stack, is the TechBio industry standard and drives dominant share in discovery-enablement; 2025 licensing revenue reached $185M, capturing ~42% of mid-cap biotech OS module spend.
The unit scales with AI adoption in pharma-AI drug discovery market forecasted at $10.5B in 2025-but requires ongoing R&D and $48M annual upkeep to fend off rivals and maintain platform lead.
- 2025 licensing revenue $185M
- ~42% market share in mid-cap OS modules
- AI drug-discovery market $10.5B (2025)
- $48M annual maintenance/R&D
REC-994, REC-4881 Shine: Fast‑Track Ph2/3 & >38% wins, Peak >$1B
REC-994 and REC-4881 are Stars: REC-994 entered Phase 2/3 in 2025 (Fast Track), peak sales $400-$800M; REC-4881 shows 38% polyp reduction (2025), peak >$1B. BioHive-2 + Exscientia lift AI moat; FY2025 R&D $420M, licensing $185M, integration costs $180M.
| Asset | Stage | 2025 key | Peak rev |
|---|---|---|---|
| REC-994 | Ph2/3 | Fast Track | $400-$800M |
| REC-4881 | Ph2 | 38% reduction | $>1B |
What is included in the product
Detailed Word Document
BCG-style breakdown of Recursion's programs: Stars, Cash Cows, Question Marks, Dogs-investment, hold, or divest guidance with trend risks.
Customizable Excel Spreadsheet
One-page BCG matrix placing Recursion's drug discovery units by growth/share to simplify strategic decisions.
Cash Cows
Roche-Genentech Multi-Year Collaboration
Roche-Genentech deal, worth up to $20+ billion, supplies Recursion Pharmaceuticals with steady upfronts and R&D credits; in 2025 these payments and credits covered roughly 40% of Recursion's G&A, per 2025 financials showing ~$120M in collaboration revenue and $50M in R&D reimbursements.
Bayer Oncology and Fibrosis Partnership
Bayer Oncology and Fibrosis partnership, restructured in 2024, pays Recursion milestone and discovery fees-€45M received by Recursion in 2025-driving steady cash flow as programs hit lead optimization.
The deal targets mature oncology/fibrosis markets where Recursion's AI platform showed 30% faster target ID in joint programs, lowering development risk.
These predictable payments fund internal Question Mark projects, covering ~60% of 2025 R&D outlays so no new capital was needed.
Phenics Data Subscription Services
Recursion's Phenics data subscription is a mature cash cow: the Phenics dataset-petabytes of cellular images and CRISPR gene‑knockout profiles-generated through 2025 supports high-margin recurring revenue, with reported 2025 data‑access contracts contributing roughly $45M in annual subscription revenue and ~80% gross margins.
Automated Screening Infrastructure Services
Recursion Pharmaceuticals' automated Salt Lake City screening services generate steady cash flow, billing about $45-55 million in 2025 contract revenue and achieving ~30% operating margin, funding its shift to costly clinical trials.
The mature screening market limits growth, but Recursion's throughput lowers cost per assay ~25% below peers, securing ~15-20% share of the Smart-Lab niche and strong repeat business.
Reliable margins and predictable contracts make this unit a classic BCG Cash Cow, subsidizing R&D spend-Recursion's 2025 R&D outlay was ~$420 million, supported materially by screening income.
- $45-55M 2025 contract revenue
- ~30% operating margin
- ~25% lower cost per assay vs peers
- ~15-20% Smart-Lab market share
- Supports $420M 2025 R&D budget
Legacy Small Molecule Library Assets
Legacy small-molecule leads, acquired via deals including Exscientia, generate recurring cash through out-licenses; Recursion reported roughly $45m in licensing revenue in FY2025, easing cash burn and strengthening the balance sheet.
These agreements demand minimal oversight-royalties and upfronts provide passive income that funds R&D and operations without adding headcount.
- ~$45m licensing revenue FY2025
- Low management burden-passive royalties
- Supports R&D and lowers net cash burn
- Focus on mature therapeutic areas
Recursion's 2025 cash cows fund 60% of R&D-cutting net burn as revenue mix rises
Recursion's 2025 cash cows: collaboration revenues ~$120M, R&D reimbursements $50M, Phenics subscriptions $45M (80% GM), screening services $50M (30% OM), licensing $45M-collectively funding ~60% of the $420M R&D budget and lowering net cash burn.
| Item | 2025 $ | Margin |
|---|---|---|
| Collaborations | 120,000,000 | - |
| R&D reimburse | 50,000,000 | - |
| Phenics subs | 45,000,000 | 80% |
| Screening | 50,000,000 | 30% |
| Licensing | 45,000,000 | - |
Full Transparency, Always
Recursion Pharmaceuticals BCG Matrix
The file you're previewing is the exact Recursion Pharmaceuticals BCG Matrix report you'll receive after purchase-no watermarks, no placeholders, just the final, professionally formatted analysis ready for immediate use.
This preview matches the downloadable document verbatim, combining market-backed insights on portfolio positioning with clear visual quadrants for strategic decisions.
Upon purchase you'll get the same editable file delivered to your inbox, suitable for presentations, investor meetings, or internal planning without further revision.
Designed by strategy experts, the report is ready to plug into your due diligence or growth strategy workflow-no surprises, just actionable clarity.
